Article Text

Download PDFPDF
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes
  1. Camilla Nero1,
  2. Anna Fagotti1,
  3. Gian Franco Zannoni2,
  4. Eleonora Palluzzi1,
  5. Giovanni Scambia1 and
  6. Marco Petrillo3
  1. 1 Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Ginecologia Oncologica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia
  2. 2 Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Gineco-patologia e Patologia Mammaria, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia
  3. 3 Universita degli Studi di Sassari Facolta di Medicina e Chirurgia, Sassari, Italia
  1. Correspondence to Dr Camilla Nero, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy; camillanero{at}gmail.com

Abstract

Background Growing evidence supports the role of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer. Currently, there is no shared histopathologic scoring system to assess pathologic response in the specimens obtained at interval surgery after neoadjuvant chemotherapy This review aims to summarize the literature on pathologic response, focusing on proposed scoring systems.

Methods The systematic review was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, focusing on the definition of pathologic response, its prognostic value, possible predictors, and future implications. Eighteen manuscripts focusing on pathologic response in epithelial ovarian cancer were selected for analysis.

Results Overall, eight histopathologic scoring systems to evaluate pathologic response have been proposed. There are currently no available markers (serum, radiological, genomic) to select which patients could achieve the highest benefit from neoadjuvant chemotherapy experiencing a complete pathologic response. A three-tier scoring system (CRS) based on omental assessment and which classifies the response to neoadjuvant chemotherapy has been validated in external cohorts of epithelial ovarian cancer. This scoring system demonstrated adequate interobserver reproducibility. Data is limited on the pathologic complete response rate changes according to chemotherapy regimen.

Conclusions A histopathologic scoring system endowed with prognostic value could be helpful in personalizing the treatment decision in patients with epithelial ovarian cancer.

  • ovarian cancer
  • neoadjuvant chemotherapy
  • pathologic response
  • interval debulking surgery

Statistics from Altmetric.com

Footnotes

  • Contributors CN, AF, GFZ, EP, GS, and MP contributed to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.